Generate Biomedicines, Inc. (GENB) Stock

About Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

Generate Biomedicines, Inc. is headquartered in US.

Generate Biomedicines, Inc. (GENB) stock trades at $13.89 with a market capitalization of $1.78B. The stock is valued at a price-to-earnings (P/E) ratio of -2.79, price-to-book of -1.13, price-to-sales of 55.83. Over the past 52 weeks the stock has ranged between $11.00 and $18.18, and currently trades 23.6% below its 52-week high.

On profitability, Generate Biomedicines, Inc. generates a return on equity (ROE) of 38.68% — well above the market average, a sign of a high-quality business, return on capital employed of -94.79%, an operating margin of -737.04%, a net profit margin of -636.99%.

Official website: generatebiomedicines.com